A rhodamine-derived, membrane-permeable fluorophore (DAR-4M AM) sensitive to nitric oxide production has been developed recently. The authors evaluated this reagent in both 96-and 384-well formats using heterologously expressed neuronal nitric oxide synthase (nNOS). nNOS transfected into HEK-293T cells was stimulated by the addition of ionomycin. The calcium mobilization resulting from ionomycin treatment of nNOS-expressing 293T cells induced a robust increase in emission intensity, as measured using a standard rhodamine filter set. The effect was time dependent, and a 3-to 4-fold stimulation could be achieved in a 2-h time period. Ionomycin-dependent nitric oxide (NO) production was completely inhibited by several arginine analogs at micromolar concentrations (e.g., L-NAME IC 50 = 3.0 µM). Several arginine analog inhibitors of nNOS were revealed to be differentially reversible over increasing substrate concentrations. The assay is a facile method for characterizing inhibitors of nNOS in a relatively unperturbed cell environment. (Journal of Biomolecular Screening 2005:849-855) 
INTRODUCTION
N ITRIC OXIDE IS A FREELY DIFFUSIBLE 2nd messenger that has been implicated in a variety of physiologic functions. 1 There are 3 isoforms of the nitric oxide synthase enzymes that are encoded by 3 distinct genes (endothelial or eNOS, inducible or iNOS, and neuronal or nNOS). The neuronal isoform (nNOS) is constitutively expressed in neurons. 2 The activity of nNOS is regulated largely by increases in intracellular calcium mediated through the activation of glutamate receptors. Activation of nNOS results in the conversion of L-arginine to L-citrulline and the generation of nitric oxide (NO). Within the brain, generation of NO can affect several neurotransmitter systems to alter neuronal excitability. 3 NO is a free radical as well as a 2nd messenger, so excessive activation of nNOS is thought to contribute to a number of pathophysiologic conditions. Modulation of nNOS activity could be a reasonable target for therapeutic intervention in a variety of neurodegenerative conditions. 4, 5 It can be challenging to efficiently evaluate small molecules for their ability to alter the function of intracellular enzymes in vivo. Frequently, cell-based assays are employed as a predictive means to assess potential in vivo activity of small molecules. In the case of nNOS, several cell-based assays have been developed to serve this purpose. 6 They include the Griess method and the radiometric measurement of 3 H-arginine to 3 H-citrulline conversion. Although both of these methods possess their own unique advantages, neither is well suited for evaluating large numbers of compounds. Recently, several molecules whose fluorescent properties are altered by direct reaction with NO have been developed. A fluorescein derivative (diaminofluorescein or DAF) was introduced first and further developed to include ester moieties that could be cleaved by intracellular enzymes, thereby preventing extrusion of the NOsensitive dye. 7 Soon thereafter, a similar strategy was used to develop a rhodamine derivative (diaminorhodamine or DAR). 8 The DAR molecule offered several practical advantages over DAF, including greater photostability.
The introduction of the DAR reagent offers the possibility to develop a cell-based assay of nNOS function that can accommodate the assessment of large numbers of compounds. We have evaluated the DAR reagent and subsequently developed a mixand-measure, cell-based assay amenable to medium-throughput evaluation of potential small-molecule inhibitors.
METHODS

Chemical reagents
N ω -Nitro-L-arginine methyl ester (L-NAME) and N ω -nitro-Larginine (NNA) were purchased from Sigma (St. Louis, MO). N 5 -[imino(methylamino)methyl]-L-ornithine (NMMA), N 5 -[imino(methylthio)methyl]-L-ornithine (MeTC), N 5 -[imino(propylamino)methyl]-L-ornithine (NPA), and 2-amino-5,6-dihydro-6-methyl-4H-1,3-thiazine (AMT) were purchased from Cayman Chemical (Ann Arbor, MI).
Transient transfection
The human embryonic kidney cell line expressing large T-antigen (HEK-293T) was obtained from the Baylor College of Medicine (Houston, TX). The DNA vector hnNos/pcDNA3.1(-)Zeo #6, encoding human nNOS, was transfected into HEK-293T cells using the cationic lipid reagent, Lipofectamine 2000 (Invitrogen, Carlsbad, CA). For experiments using transiently transfected cells, 12.5 to 50 × 10 3 cells/well were plated the following day in poly-Dlysine (PDL)-coated black-rimmed 96-well plates in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heatinactivated fetal bovine serum (FBS) for use in fluorescence experiments a day later (i.e., 48-h posttransfection).
Generation of clonal cell lines
The nNOS-transfected HEK-293T cells were grown in DMEM (Mediatech, Herndon, VA) supplemented with 10% fetal calf serum, 400 µg/mL G418 (Mediatech), and 300 µg/mL Zeocin (Invitrogen) and maintained for 3 weeks posttransfection under antibiotic selection. The nNOS-transfected HEK-293T cells were harvested from 6 well dishes using Cellstripper (Mediatech) to create a single-cell suspension. Single cells were deposited into each well of five 96-well plates using a FACSVantage flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA). The single-cell clones were fed twice weekly and eventually expanded for evaluation in the DAR assay.
Cell plating and dye loading
The day before the experiment, HEK-293T cells (transiently or stably expressing human nNOS) were plated into PDL-coated, flat, black-rimmed 96-well plates (BD Biocoat #35-6640) at a density of 12,500 to 50,000 cells/well and maintained overnight in DMEM (Mediatech) supplemented with 10% heat-inactivated fetal bovine serum and 2 mM glutamine. The following day, the culture medium was removed, and adherent cells were washed once (200 µL/well) with dye-loading buffer before exposure to DAR-4M AM (Calbiochem). The dye-loading buffer is a phenol redfree Hank's balanced salt solution (HBSS) (Bio-Whittaker) supplemented with 150 µM arginine. Washed cells were loaded with 10 µM DAR-4M AM (0.2% DMSO) in loading buffer (100 µL/ well) for 30 to 40 min at 37°C. At the end of the labeling period, wells were diluted with an equal volume of wash buffer. Diluted labeling buffer was removed, and cells were washed once with wash buffer (200 µL/well).
Assay protocol
The assay was conducted in a total volume of 100 µL/well in assay buffer and included 60 µL/well assay buffer added to loaded, washed cells, as well as 20 µL/well compound dilution or compound vehicle in assay buffer at 5× the desired final concentration. Following incubation with or without inhibitor for 10 to 20 min at room temperature, 20 µL/well vehicle control or ionomycin was added at 5× the desired final concentration (10 µM) in assay buffer to initiate nNOS activation. The mixture was then incubated for 2 h at 37°C.
Assay buffer
In the course of developing this assay for use in the 96-well format, we used and tested both Dulbecco's phosphate-buffered saline (D-PBS) and N-(2-hydroxyethyl)piperazine-N′-(2ethanesulfonic acid); HEPES-buffered saline as the assay buffer. Both D-PBS (Mediatech) and HEPES-buffered saline (25 mM HEPES, 150 mM NaCl, 0.8 mM Na 2 HPO 4 , 5.4 mM KCl, 0.5 mM MgCl 2 , 0.9 mM CaCl 2 ) with 10 mM dextrose (pH = 7.4) were supplemented with arginine as described.
Instrumentation
To monitor NO production, the formation of DAR4M-T was quantitated by measuring fluorescence intensity on either an LJL Analyst (Molecular Devices Corporation or MDC) or Gemini XS (MDC) fluorescence plate reader. The LJL Analyst instrument was set with excitation filters at rhodamine 530/25 nm, emission filters at rhodamine 580/10 nm, and the beam splitter at RH561/bottom read. The Gemini XS instrument was set with excitation at 530 nm, emission at 580 nm, and the cutoff filter at 570 nm.
Data analysis
Data were routinely exported to Excel and analyzed in GraphPad Prism. Data in graphs and tables are expressed as mean fluorescence intensity, mean stimulation index (ratio of fluorescence intensity for ionomycin treated/basal), and mean percent maximum control ± standard error of the mean (SEM). Concentration response curves were fit in GraphPad Prism via nonlinear regression for median effective concentration (EC 50 ) and the 50% inhibitory concentration (IC 50 ) determinations. Where data are normalized, maximum response (100%) is defined as the response to 10 µM ionomycin.
RESULTS
As previously reported, the acetoxy-methyl ester of diaminorhodamine (DAR-4M AM) is a cell-permeable fluorophore. 8 Intracellular esterases cleave the acetoxy-methyl moiety, produc-ing the free acid form of diaminorhodamine (DAR-4M). Upon reaction with NO in the presence of oxygen (O 2 ), the triazolorhodamine analog, DAR4M-T, is formed. DAR4M-T exhibits about 840-fold greater fluorescence quantum efficiency than DAR-4M. Therefore, in the presence of sufficient oxygen, DAR4M-T AM acts as a sensitive fluorescent detector of cytosolic NO.
In response to ionomycin stimulation, cells expressing nNOS and labeled with DAR-4M AM exhibited a time-dependent increase in fluorescence intensity ( Fig. 1 ). Cells without heterologously expressed nNOS, unstimulated cells, and cells with excess inhibitor did not exhibit a time-dependent increase in fluorescence intensity. nNOS production appeared to be biphasic over the 2-h time period in this experiment, but when normalized to control (i.e., vehicle treated), the NO production curve seems monophasic. Detailed progress curves were better fit with a single exponential model (Fig. 2 inset) . In cells with stably transfected nNOS, L-NAME inhibited the formation of DAR4M-T induced by 10 µM ionomycin in a concentration-dependent manner (Fig. 2 ). In these initial conditions, the esterase-sensitive prodrug, L-NAME, reversed nNOS enzyme activity with an IC 50 of 3.0 µM. These early observations suggested that the system could be further optimized for robustness of signal and used to probe the properties of nNOS inhibitors in a heterologous cellular environment.
Under optimized conditions, progress curves following DAR4M-T formation over a 100-min time period were generated ( Fig. 2 inset) . In accordance with the single time point data, DAR4M-T formation was reduced in the presence of increasing concentrations of L-NAME.
Detection of stimulated nNOS was sensitive to cell density in both 96-and 384-well formats ( Fig. 3 ). Optimal signal-tobackground ratios were achieved in nearly confluent densities. The assay was also found to be relatively insensitive to DMSO at concentrations up to 0.5% (Fig. 3c ). Furthermore, the signal window was enhanced considerably when the assay buffer was supplemented with 10 mM dextrose (Fig. 4 ). The supplemental dextrose may increase oxygen or enzyme cofactor availability. 2 However, no experiments were carried out to address these hypotheses.
Ionomycin was used to stimulate nNOS activity in all experiments. Ionomycin is an ionophore that enables the transmembrane permeability of ions. 9 The concentration of extracellular calcium ions was varied to demonstrate the dependence of nNOS activity on calcium-calmodulin. Measured NO production rose sharply in response to increasing concentrations of extracellular calcium (Fig. 4) . The EC 50 for calcium in the presence of 10 mM dextrose was 0.44 mM, and in the absence of dextrose, it was 0.31 mM. Subsequent experiments were performed in the presence of a calcium concentration necessary to obtain maximal stimulation (0.9 Figs. 3 and 4 ). Cells not stimulated with ionomycin (+) were also included. All L-NAME data were fit with a 1phase exponential model. mM). The signal was slightly less robust when carried out in a phosphate buffer. With the conditions sufficiently optimized, several well-known inhibitors of nNOS were evaluated in the assay (Fig. 5) . A rank order potency of L-NAME ≥ AMT > NMMA > NPA was found in the presence of 150 µM L-arginine (3.2, 3.5, 16, and 270 µM, respectively). In general, these potency values are considerably right-shifted from those reported using cell-free assays. 10, 11 This shift in potency has been observed in other systems. 12 The rank order potency of these standards was similar to that found in cell-free assays. 11 However, L-NAME appeared relatively more potent in the cell-based assay, possibly as a consequence of an increased intracellular concentration resulting from cleavage of the ester moiety. Potency of the arginine analog inhibitors could also be affected by the concentration of substrate, further validating that the measured NO production was a consequence of enzymatic activity.
The substrate concentration was adjusted by varying the amount of supplemental L-arginine included in the extracellular buffer. The final intracellular concentration of L-arginine was not measured. Nevertheless, the IC 50 s of most inhibitors shifted in the face of increasing concentrations of available substrate (Fig. 6) . A nonparametric global ANOVA test (Kruskal-Wallis) of the resulting curve fits produced a p-value < 0.0001. Dunn multiplecomparison test of the most extreme conditions (i.e., no supplemental L-arginine vs. 150 µM) yielded p-values < 0.0001 for all 4 FIG. 3. (a) Ionomycin-induced DAR4M-T formation sensitive to N ω -nitro-L-arginine methyl ester (L-NAME) was detected in a 384-well plate format in transiently transfected cells that express neuronal nitric oxide synthase (n-NOS). The nNOS-transfected cells were loaded with 10 µM DAR-4M AM for 40 min in phenol red-free Dulbecco's modified Eagle's medium (DMEM) supplemented with 300 µM arginine and washed to remove unincorporated dye in 384-well plates. After preincubation without () or with () 300 µM L-NAME, labeled cells that had been plated at the indicated density were treated with 10 µM ionomycin. Singlicate data shown are for the 4 × inhibitors, although comparison of several intermediate conditions did not reach significance. Despite statistical significance, neither the IC 50 of NNA nor the corresponding methyl ester, L-NAME, appeared to be very sensitive to differential substrate concentrations.
Following this observation, the concentration of extracellular L-arginine concentration was varied more broadly, and a selection of arginine analog inhibitors was evaluated. The IC 50 s determined under the variable substrate conditions were compared to the respective IC 50 s of the baseline condition (i.e., no supplemental Larginine for each inhibitor), producing a "fold-shift" in IC 50 . The resulting shift in IC 50 values was plotted as a function of the Larginine concentration for 5 arginine analog inhibitors (Fig. 7) . When the data were fit with a sigmoidal curve, the calculated midpoint of L-arginine dependence was 350 to 490 µM for NPA, 240 to 510 µM for MeTC, and 560 to 720 µM for NMMA (95% confidence intervals). The extent of the shift in inhibitor IC 50 s varied from 30-to 60-fold.
DISCUSSION
Previously, DAR-4M AM has been reported to detect the formation of NO in a native cell environment. 8 In that seminal report, the authors used cultured bovine aortic endothelial cells to demonstrate a ratiometric fluorescence change following stimulation by a single concentration of bradykinin. Here, we extend on that work and report the development of a robust method for evaluating inhibitors of heterologously expressed NO synthase using a singleemission measurement to track the formation of DAR4M-T. The assay is amenable to 96-and 384-well configurations and can be run on several standard fluorescent plate readers. The assay was optimized for signal strength and can accommodate up to 0.5% DMSO. We further demonstrate the utility of the assay by validating it with a number of known inhibitors of nNOS.
In evaluating the assay with several known inhibitors, we observed that the inhibitor compounds were generally less potent than those from reports using purified enzyme preparations. Similar findings have been reported from others, although we did not observe the right-shift in potency with all compounds. 12 The rightshifted potencies may be the result of restricted access to the intracellular enzyme. This suggests that the assay should be able to better predict the inhibitory properties of compounds in vivo than values derived from a purified enzyme preparation.
With isolated enzyme preparations from porcine brain, NNA was demonstrated to be a slowly reversible inhibitor of nNOS. 13 L-NAME also dissociates very slowly from the enzyme complex. 11 Increasing the concentration of extracellular arginine did not alter the IC 50 s of L-NAME or NNA. As such, both L-NAME and NNA appeared to behave like irreversible inhibitors in this assay format. L-NAME was about 1.5-to 2-fold more potent than NNA at all substrate concentrations.
The potencies of the other inhibitors (NPA, MeTC, and NMMA) were affected by increasing substrate availability. So, they appeared to behave like competitive inhibitors in this assay format. When challenged with increasing concentrations of substrate, the IC 50 s of these inhibitors shifted rightward. Notably, the shift in all 3 competitive inhibitor IC 50 s appeared to plateau in the supplemental arginine concentration range of 0.5 to 1 mM. This limitation may represent the capacity for increasing cytosolic arginine concentration through extracellular supplementation. Arginine is reported to cross plasma membranes through active transport. 14 Indeed, substrate-based inhibitors have also been reported to undergo active transport. 15 The arginine transport capacity of HEK-T cells has not been reported. We could make kinetic measurements that tracked DAR4M-T formation over time. However, we did not attempt to measure classic enzyme parameters (e.g., V max ) primarily because substrate concentration cannot be tightly controlled in this cellular system.
Overall, the assay provides a rapid and convenient method for evaluating nNOS inhibitors in a homogeneous cellular format. It yields a robust response and exhibits a pharmacologic profile consistent with previous reports. It should be possible to use the assay in a search for new therapeutic entities. 
